Kunpeng Gene (Beijing) Technology Co., Ltd. has successfully concluded a Series B financing round that surpassed RMB 100 million, with Taiping Healthcare Fund taking the lead. The infused capital will primarily fuel the acceleration of R&D initiatives for innovative product pipelines, including tuberculosis and drug resistance diagnostics, and support the company's market expansion efforts. Established in 2016, Kunpeng Gene is dedicated to transforming cutting-edge life science research technology into clinically relevant products. Leveraging precise temperature control technology and a state-of-the-art microfluidic detection platform, the company offers efficient and precise biosafety detection solutions. In July 2023, Kunpeng Gene relocated to its Beijing headquarters, which boasts a research and development operation center spanning over 10,000 square meters, along with a production and intelligent manufacturing center located at its Xuzhou subsidiary.